{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:49:54Z","timestamp":1792172994915,"version":"4.4.0"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,16]]},"DOI":"10.1093\/ibd\/izx065","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T17:40:20Z","timestamp":1518802820000},"page":"539-545","source":"Crossref","is-referenced-by-count":58,"title":["Combination Immunosuppression in IBD"],"prefix":"10.1093","volume":"24","author":[{"given":"Steven","family":"Bots","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Gecse","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Barclay","sequence":"additional","affiliation":[{"name":"Departments of Gastroenterology & Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"D\u2019Haens","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,2,16]]},"reference":[{"key":"key\n\t\t\t\t20180305101527_CIT0001","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the accent i randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180305101527_CIT0002","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180305101527_CIT0003","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180305101527_CIT0004","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180305101527_CIT0005","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0006","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0007","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0008","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180305101527_CIT0009","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180305101527_CIT0010","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180305101527_CIT0011","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn\u2019s disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180305101527_CIT0012","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180305101527_CIT0013","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn\u2019s disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180305101527_CIT0014","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cgh.2015.10.029","article-title":"Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis","volume":"14","author":"Brandse","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180305101527_CIT0016","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn\u2019s disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0017","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180305101527_CIT0018","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1097\/MIB.0000000000000208","article-title":"Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD","volume":"20","author":"van Schaik","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180305101527_CIT0019","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/MIB.0000000000001203","article-title":"Systematic review and meta-analysis: adalimumab monotherapy versus combination therapy with immunomodulators for induction and maintenance of remission and response in patients with Crohn\u2019s disease","volume":"23","author":"Chalhoub","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180305101527_CIT0020","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","article-title":"Adalimumab monotherapy and a combination with azathioprine for Crohn\u2019s disease: a prospective, randomized trial","volume":"10","author":"Matsumoto","year":"2016","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180305101527_CIT0021","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180305101527_CIT0022","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/apt.13994","article-title":"Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease","volume":"45","author":"Strik","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180305101527_CIT0023","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/j.gastro.2017.07.021","article-title":"Anti-tumor necrosis factor with a glyco-engineered Fc-region has increased efficacy in mice with colitis","volume":"153","author":"Bloemendaal","year":"2017","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0024","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ibd.21818","article-title":"Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro","volume":"18","author":"Vos","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180305101527_CIT0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2010.10.008","article-title":"Anti-tumor necrosis factor-\u03b1 antibodies induce regulatory macrophages in an Fc region-dependent manner","volume":"140","author":"Vos","year":"2011","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0026","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/mi.2016.65","article-title":"The ATG16L1 risk allele associated with Crohn\u2019s disease results in a rac1-dependent defect in dendritic cell migration that is corrected by thiopurines","volume":"10","author":"Wildenberg","year":"2017","journal-title":"Mucosal Immunol"},{"key":"key\n\t\t\t\t20180305101527_CIT0027","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/apt.13102","article-title":"Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. Infliximab alone for active ulcerative colitis","volume":"41","author":"Christophorou","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180305101527_CIT0028","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180305101527_CIT0029","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/MIB.0000000000001183","article-title":"Thiopurines dosed to a therapeutic 6-thioguanine level in combination with adalimumab are more effective than subtherapeutic thiopurine-based combination therapy or adalimumab monotherapy during induction and maintenance in patients with long-standing Crohn\u2019s disease","volume":"23","author":"Kariyawasam","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180305101527_CIT0030","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/apt.12076","article-title":"Does co-treatment with immunosuppressors improve outcome in patients with Crohn\u2019s disease treated with adalimumab","volume":"36","author":"Reenaers","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180305101527_CIT0031","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/apt.13808","article-title":"Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn\u2019s disease","volume":"44","author":"Cosnes","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180305101527_CIT0032","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/00365521.2017.1304987","article-title":"Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish national quality registry for inflammatory bowel disease (SWIBREG)","volume":"52","author":"Eriksson","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t20180305101527_CIT0033","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn\u2019s disease: results from the US VICTORY consortium","volume":"111","author":"Dulai","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180305101527_CIT0034","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/apt.13813","article-title":"Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease\u2014a prospective multicenter observational study","volume":"44","author":"Stallmach","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180305101527_CIT0035","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1007\/s10620-017-4549-3","article-title":"Predictors of clinical response and remission at 1 year among a multicenter cohort of patients with inflammatory bowel disease treated with vedolizumab","volume":"62","author":"Allegretti","year":"2017","journal-title":"Dig Dis Sci"},{"key":"key\n\t\t\t\t20180305101527_CIT0036","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180305101527_CIT0037","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.cgh.2017.03.032","article-title":"Association among ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn\u2019s disease","volume":"15","author":"Battat","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180305101527_CIT0038","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the coin study","volume":"63","author":"van der Valk","year":"2014","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180305101527_CIT0039","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.gastro.2011.09.034","article-title":"Maintenance of remission among patients with Crohn\u2019s disease on antimetabolite therapy after infliximab therapy is stopped","volume":"142","author":"Louis","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0040","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn\u2019s disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0041","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/apt.14106","article-title":"Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial","volume":"46","author":"Roblin","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180305101527_CIT0042","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180305101527_CIT0043","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S1542-3565(04)00414-8","article-title":"Long-term treatment of rectovaginal fistulas in Crohn\u2019s disease: response to infliximab in the ACCENT II study","volume":"2","author":"Sands","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180305101527_CIT0044","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180305101527_CIT0045","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0046","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0047","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.autrev.2017.04.002","article-title":"The impact of immunogenicity of TNF\u03b1 inhibitors in autoimmune inflammatory disease. a systematic review and meta-analysis","volume":"16","author":"Pecoraro","year":"2017","journal-title":"Autoimmun Rev"},{"key":"key\n\t\t\t\t20180305101527_CIT0048","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjw133","article-title":"Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2\/3 PURSUIT induction and maintenance studies","volume":"11","author":"Adedokun","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180305101527_CIT0049","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ajg.2012.89","article-title":"a pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180305101527_CIT0050","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2013.441","article-title":"Drug therapies and the risk of malignancy in Crohn\u2019s disease: results from the TREAT\u2122 registry","volume":"109","author":"Lichtenstein","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180305101527_CIT0051","first-page":"680","article-title":"Five-year safety data from ENCORE, a European observational safety registry for adults with Crohn\u2019s disease treated with infliximab [Remicade\u00ae] or conventional therapy","volume":"11","author":"D\u2019Haens","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20180305101527_CIT0052","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn\u2019s disease","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0053","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1016\/S0016-5085(17)30790-4","article-title":"Long-term safety of adalimumab in patients with Crohn\u2019s disease: final data from PYRAMID registry","volume":"152","author":"D\u2019Haens","year":"2017","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0054","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180305101527_CIT0055","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1097\/01.MIB.0000480259.39258.ac","article-title":"P-104 SECURE: an observational study of certolizumab pegol in Crohn\u2019s disease-events of interest analysis with 5869 patient-years at risk","volume":"22","author":"Lee","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180305101527_CIT0056","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0057","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180305101527_CIT0058","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0059","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a Prospective Observational Cohort Study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180305101527_CIT0060","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20180305101527_CIT0061","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am j Epidemiol"},{"key":"key\n\t\t\t\t20180305101527_CIT0062","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180305101527_CIT0063","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: inflammatory bowel disease and malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J Crohns Colitis"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/24\/3\/539\/24250546\/izx065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T15:15:45Z","timestamp":1520262945000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/3\/539\/4863712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,16]]},"references-count":63,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,2,16]]},"published-print":{"date-parts":[[2018,2,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izx065","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3]]},"published":{"date-parts":[[2018,2,16]]}}}